PTC Therapeutics, Inc.
PTCT
$73.46
-$1.56-2.08%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 65.51% | -21.96% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 65.51% | -21.96% | |||
| Cost of Revenue | -72.05% | 20.82% | |||
| Gross Profit | 848.79% | -74.12% | |||
| SG&A Expenses | -11.04% | 15.26% | |||
| Depreciation & Amortization | 23.87% | 24.09% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -7.97% | 18.69% | |||
| Operating Income | 156.22% | -2,440.14% | |||
| Income Before Tax | 98.23% | -502.77% | |||
| Income Tax Expenses | 108.43% | 89.43% | |||
| Earnings from Continuing Operations | 97.92% | -949.05% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 97.92% | -949.05% | |||
| EBIT | 156.22% | -2,440.14% | |||
| EBITDA | 189.20% | -570.80% | |||
| EPS Basic | 97.97% | -925.57% | |||
| Normalized Basic EPS | 98.21% | -365.05% | |||
| EPS Diluted | 97.97% | -957.30% | |||
| Normalized Diluted EPS | 98.21% | -416.25% | |||
| Average Basic Shares Outstanding | 2.27% | 2.83% | |||
| Average Diluted Shares Outstanding | 2.27% | -7.38% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||